These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27718183)

  • 21. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
    Ma R; Du JL; Huang J; Wu CY
    Biochem Biophys Res Commun; 2007 Sep; 361(2):537-42. PubMed ID: 17662694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.
    Davis HL; Suparto II; Weeratna RR; Jumintarto ; Iskandriati DD; Chamzah SS; Ma'ruf AA; Nente CC; Pawitri DD; Krieg AM; Heriyanto ; Smits W; Sajuthi DD
    Vaccine; 2000 Mar; 18(18):1920-4. PubMed ID: 10699341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.
    Janssen JM; Heyward WL; Martin JT; Janssen RS
    Vaccine; 2015 Feb; 33(7):833-7. PubMed ID: 25576215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine.
    Moon SH; Shin EC; Noh YW; Lim YT
    Vaccine; 2015 Sep; 33(38):4762-9. PubMed ID: 26271830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CpG oligodeoxynucleotide enhances humoral and cellular immune responses against HBsAg in mice].
    Zhou Z; Chen WS; Yao JL
    Zhonghua Nei Ke Za Zhi; 2003 Sep; 42(9):640-2. PubMed ID: 14514394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.
    Siegrist CA; Pihlgren M; Tougne C; Efler SM; Morris ML; AlAdhami MJ; Cameron DW; Cooper CL; Heathcote J; Davis HL; Lambert PH
    Vaccine; 2004 Dec; 23(5):615-22. PubMed ID: 15542181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanodecoy system: a novel approach to design hepatitis B vaccine for immunopotentiation.
    Goyal AK; Rawat A; Mahor S; Gupta PN; Khatri K; Vyas SP
    Int J Pharm; 2006 Feb; 309(1-2):227-33. PubMed ID: 16406404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy.
    Barry M; Cooper C
    Expert Opin Biol Ther; 2007 Nov; 7(11):1731-7. PubMed ID: 17961095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.
    Janssen JM; Jackson S; Heyward WL; Janssen RS
    Vaccine; 2015 Jul; 33(31):3614-8. PubMed ID: 26067185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses.
    Julier Z; de Titta A; Grimm AJ; Simeoni E; Swartz MA; Hubbell JA
    Vaccine; 2016 May; 34(21):2453-2459. PubMed ID: 27016652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine self-assembling immune matrix is a new delivery platform that enhances immune responses to recombinant HBsAg in mice.
    Grenfell RF; Shollenberger LM; Samli EF; Harn DA
    Clin Vaccine Immunol; 2015 Mar; 22(3):336-43. PubMed ID: 25609075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant.
    Champion CR
    Ann Pharmacother; 2021 Jun; 55(6):783-791. PubMed ID: 32988213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen.
    Xie Y; Sun HX; Li D
    Vaccine; 2009 Jan; 27(5):757-64. PubMed ID: 19041358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RLJ-NE-299A: a new plant based vaccine adjuvant.
    Khajuria A; Gupta A; Singh S; Malik F; Singh J; Suri KA; Satti NK; Qazi GN; Srinivas VK; Gopinathan ; Ella K
    Vaccine; 2007 Mar; 25(14):2706-15. PubMed ID: 16872726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HBV-ISS (Dynavax).
    Sung JJ; Lik-Yuen H
    Curr Opin Mol Ther; 2006 Apr; 8(2):150-5. PubMed ID: 16610768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.
    Halperin SA; Ward BJ; Dionne M; Langley JM; McNeil SA; Smith B; Mackinnon-Cameron D; Heyward WL; Martin JT
    Hum Vaccin Immunother; 2013 Jul; 9(7):1438-44. PubMed ID: 23571179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic innate defense regulator peptide combination using CpG ODN as a novel adjuvant induces long‑lasting and balanced immune responses.
    Yu CH; Luo ZC; Li M; Lu L; Li Z; Wu XZ; Fan YZ; Zhang HL; Zhou BL; Wan Y; Men K; Tian YM; Chen S; Yuan FJ; Xiang R; Yang L
    Mol Med Rep; 2016 Jan; 13(1):915-24. PubMed ID: 26647852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between tightness of binding and immunogenicity in an aluminum-containing adjuvant-adsorbed hepatitis B vaccine.
    Egan PM; Belfast MT; Giménez JA; Sitrin RD; Mancinelli RJ
    Vaccine; 2009 May; 27(24):3175-80. PubMed ID: 19446188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The orientation of CpG conjugation on aluminum oxyhydroxide nanoparticles determines the immunostimulatory effects of combination adjuvants.
    Liang Z; Bao H; Yao Z; Li M; Chen C; Zhang L; Wang H; Guo Y; Ma Y; Yang X; Yu G; Zhang J; Xue C; Sun B; Mao C
    Biomaterials; 2024 Jul; 308():122569. PubMed ID: 38626556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.